Cargando…

Second Line Palliative Endobronchial Radiotherapy with HDR Ir 192 in Recurrent Lung Carcinoma

PURPOSE: To observe the efficiency of reirradiation with high dose rate intraluminal brachytherapy in symptomatic palliation of recurrent endobronchial tumors. MATERIALS AND METHODS: Between January 1994 and June 1998, 21 patients diagnosed with recurrent endobronchial tumors following external beam...

Descripción completa

Detalles Bibliográficos
Autores principales: Zorlu, A. Faruk, Selek, Ugur, Emri, Salih, Gurkaynak, Murat, Akyol, Fadil H.
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615289/
https://www.ncbi.nlm.nih.gov/pubmed/18729305
http://dx.doi.org/10.3349/ymj.2008.49.4.620
_version_ 1782163306161635328
author Zorlu, A. Faruk
Selek, Ugur
Emri, Salih
Gurkaynak, Murat
Akyol, Fadil H.
author_facet Zorlu, A. Faruk
Selek, Ugur
Emri, Salih
Gurkaynak, Murat
Akyol, Fadil H.
author_sort Zorlu, A. Faruk
collection PubMed
description PURPOSE: To observe the efficiency of reirradiation with high dose rate intraluminal brachytherapy in symptomatic palliation of recurrent endobronchial tumors. MATERIALS AND METHODS: Between January 1994 and June 1998, 21 patients diagnosed with recurrent endobronchial tumors following external beam radiotherapy were treated palliatively with high dose rate intraluminal irradiation at Hacettepe University Oncology Institute. A single fraction of 10 Gy was prescribed to the specified area in 9 patients and 15 Gy to 12. RESULTS: Endobronchial treatment improved the performance and reduced symptomatology in 17 (81%) patients. Ten dyspneic patients (10/14, 71%) recovered clinically with an accompanying radiological downstaging. The median symptomatic palliation was 45 days (range, 0 - 9 months), and the overall median survival was 5.5 months (range, 4 - 12 months). The palliative intrabronchial brachytherapy was well tolerated, with the exception of in one patient with a fatal hemorrhage, and another with medically salvaged bronchospasm and intrabronchial edema. CONCLUSION: Recurrent patients with a history of previous thoracic external beam irradiation can be effectively palliated with high dose rate endobronchial reirradiation if the symptoms are directly related to the endobronchial tumor.
format Text
id pubmed-2615289
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-26152892009-02-02 Second Line Palliative Endobronchial Radiotherapy with HDR Ir 192 in Recurrent Lung Carcinoma Zorlu, A. Faruk Selek, Ugur Emri, Salih Gurkaynak, Murat Akyol, Fadil H. Yonsei Med J Original Article PURPOSE: To observe the efficiency of reirradiation with high dose rate intraluminal brachytherapy in symptomatic palliation of recurrent endobronchial tumors. MATERIALS AND METHODS: Between January 1994 and June 1998, 21 patients diagnosed with recurrent endobronchial tumors following external beam radiotherapy were treated palliatively with high dose rate intraluminal irradiation at Hacettepe University Oncology Institute. A single fraction of 10 Gy was prescribed to the specified area in 9 patients and 15 Gy to 12. RESULTS: Endobronchial treatment improved the performance and reduced symptomatology in 17 (81%) patients. Ten dyspneic patients (10/14, 71%) recovered clinically with an accompanying radiological downstaging. The median symptomatic palliation was 45 days (range, 0 - 9 months), and the overall median survival was 5.5 months (range, 4 - 12 months). The palliative intrabronchial brachytherapy was well tolerated, with the exception of in one patient with a fatal hemorrhage, and another with medically salvaged bronchospasm and intrabronchial edema. CONCLUSION: Recurrent patients with a history of previous thoracic external beam irradiation can be effectively palliated with high dose rate endobronchial reirradiation if the symptoms are directly related to the endobronchial tumor. Yonsei University College of Medicine 2008-08-30 2008-08-30 /pmc/articles/PMC2615289/ /pubmed/18729305 http://dx.doi.org/10.3349/ymj.2008.49.4.620 Text en Copyright © 2008 The Yonsei University College of Medicine http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Zorlu, A. Faruk
Selek, Ugur
Emri, Salih
Gurkaynak, Murat
Akyol, Fadil H.
Second Line Palliative Endobronchial Radiotherapy with HDR Ir 192 in Recurrent Lung Carcinoma
title Second Line Palliative Endobronchial Radiotherapy with HDR Ir 192 in Recurrent Lung Carcinoma
title_full Second Line Palliative Endobronchial Radiotherapy with HDR Ir 192 in Recurrent Lung Carcinoma
title_fullStr Second Line Palliative Endobronchial Radiotherapy with HDR Ir 192 in Recurrent Lung Carcinoma
title_full_unstemmed Second Line Palliative Endobronchial Radiotherapy with HDR Ir 192 in Recurrent Lung Carcinoma
title_short Second Line Palliative Endobronchial Radiotherapy with HDR Ir 192 in Recurrent Lung Carcinoma
title_sort second line palliative endobronchial radiotherapy with hdr ir 192 in recurrent lung carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615289/
https://www.ncbi.nlm.nih.gov/pubmed/18729305
http://dx.doi.org/10.3349/ymj.2008.49.4.620
work_keys_str_mv AT zorluafaruk secondlinepalliativeendobronchialradiotherapywithhdrir192inrecurrentlungcarcinoma
AT selekugur secondlinepalliativeendobronchialradiotherapywithhdrir192inrecurrentlungcarcinoma
AT emrisalih secondlinepalliativeendobronchialradiotherapywithhdrir192inrecurrentlungcarcinoma
AT gurkaynakmurat secondlinepalliativeendobronchialradiotherapywithhdrir192inrecurrentlungcarcinoma
AT akyolfadilh secondlinepalliativeendobronchialradiotherapywithhdrir192inrecurrentlungcarcinoma